189. Epidemiology and Outcomes of Hospitalizations with Invasive Aspergillosis in the US, 2010-2013
Session: Poster Abstract Session: Clinical Mycology
Thursday, October 5, 2017
Room: Poster Hall CD
  • AS131-17 Isavuconazole IDWeek Epidermiology Outcomes IA Poster LB15FINAL.pdf (235.3 kB)
  • Background: Invasive aspergillosis (IA) complicates the care of up to 13% of patients with varying forms of immune compromise. The accompanying morbidity and mortality associated with IA remains high. We sought to describe the epidemiology and outcomes for all hospitalizations associated with IA in the US.

    Methods: We analyzed the National Inpatient Sample (NIS) from the Agency for Healthcare Research and Quality (AHRQ) for 2010-2013. We identified subjects with high-risk conditions for IA (stem cell or solid organ transplant, critical illness, major surgery, mild-to-moderate immune compromise, severe immune compromise and other [human immunodeficiency virus, pneumonia, chronic obstructive pulmonary disease]). IA was identified via ICD-9-CM codes 117.3, 117.9 and 484.6. We compared characteristics and outcomes between those with (IA) and without IA (non-IA). We calculated the IA-associated excess mortality, length of stay (LOS) and costs using propensity-score (PS) matching

    Results: Of the 66,634,683 discharges who met the study inclusion criteria, 154,888 (0.2%) had a diagnosis of IA. Patients with IA were more likely to be male (50.9% IA vs. 46.7% non-IA, p<0.001), and African-American (15.3% IA vs. 12.5% non-IA, p<0.001). The most common high-risk condition among those not classified as IA was major surgery (50.1%). In the IA group critical illness was noted most frequently (41.0%). The burden of both chronic (median [interquartile range, IQR] number of Elixhauser comorbidities 3 [1, 5] non-IA vs. 4 [3, 6] IA, p<0.001) and acute (median [IQR] number of procedures during the hospitalization 2 [1, 3] non-IA vs. 3 [1, 6] IA, p<0.001) illnesses was higher in the IA group than the non-IA. After PS-matching, mortality in IA (14.1%) was 37% higher than in non-IA (10.3%, p<0.001), translating to an odds ratio = 1.43; 95% CI (1.36, 1.51). IA was associated with 6.0 (95% CI 5.7, 6.4) excess days in the hospital and excess $15,542 (95% CI $13,869, $17,215) in costs/hospitalization

    Conclusion: Although rare even among high-risk groups, IA is associated with high hospital mortality, excess duration of hospitalization and costs. Given nearly 40,000 annual IA admissions in the US, we estimate that the aggregate IA-attributable excess costs may reach $600 million annually.

    Marya D. Zilberberg, MD, MPH, Evimed Research Group, LLC, Goshen, MA, Brian Nathanson, PhD, OptiStatim, LLC, Longmeadow, MA, Rachel Harrington, BA, Former Employee of Astellas Pharma Global Development, Inc, Northbrook, IL, James Spalding, PharmD, MS, MBA, Astellas Pharma Global Development, Inc., Northbrook, IL and Andrew F. Shorr, MD, MPH, Washington Hospital Center, Washington, DC


    M. D. Zilberberg, Astellas: Grant Investigator , Research support

    B. Nathanson, EviMed, LLC: Consultant , Consulting fee

    R. Harrington, Astellas Pharma Global Development, Inc: Employee , Salary

    J. Spalding, Astellas Pharma Global Development, Inc.: Employee , Salary

    A. F. Shorr, Astellas: Consultant and Speaker's Bureau , Consulting fee , Research support and Speaker honorarium
    Cidara: Consultant , Consulting fee
    Merck: Consultant , Scientific Advisor and Speaker's Bureau , Research support and Speaker honorarium

    See more of: Clinical Mycology
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.